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Objective: To evaluate the efﬁcacy of platelet-rich plasma regarding healing, pain and
hemostasis after total knee arthroplasty, by means of a blinded randomized controlled and
blinded clinical study.
Methods: Forty patients who were going to undergo implantation of a total knee prosthesis
were selected and randomized. In 20 of these patients, platelet-rich plasma was applied
before the joint capsule was closed. The hemoglobin (mg/dL) and hematocrit (%) levels were
assayed before the operation and 24 and 48 h afterwards. The Womac questionnaire and
a  verbal pain scale were applied and knee range of motion measurements were made up
to  the second postoperative month. The statistical analysis compared the results with the
aim of determining whether there were any differences between the groups at each of the
evaluation times.
Results: The hemoglobin (mg/dL) and hematocrit (%) measurements made before the opera-
tion  and 24 and 48 h afterwards did not show any signiﬁcant differences between the groups
(p  > 0.05). The Womac questionnaire and the range of motion measured before the opera-
tion  and up to the ﬁrst two months also did not show any statistical differences between
the groups (p > 0.05). The pain evaluation using the verbal scale showed that there was an
advantage for the group that received platelet-rich plasma, 24 h, 48 h, one week, three weeks
and  two months after the operation (p < 0.05).
Conclusions: In the manner in which the platelet-rich plasma was used, it was not shown to
be  effective for reducing bleeding or improving knee function after arthroplasty, in compar-
ison with the controls. There was an advantage on the postoperative verbal pain scale.©  2015 Sociedade Brasileira de Ortopedia e Traumatologia. Published by Elsevier Editora
Ltda. All rights reserved.
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Plasma  rico  em  plaquetas  (PRP)  aplicado  na  artroplastia  total  do  joelho
Palavras-chave:
Artroplastia
Joelho
Transfusão
Plasma rico em plaquetas
Hemorragia
r  e  s  u  m  o
Objetivos: Avaliar, por meio de um estudo clínico, randomizado, controlado e cego, a eﬁcácia
do  plasma rico em plaquetas na cicatrizac¸ão, dor e hemostasia após artroplastia total do
joelho.
Métodos: Foram selecionados 40 pacientes que seriam submetidos a prótese total do joelho
e  randomizados. Em 20 desses pacientes foi aplicado o plasma rico em plaquetas antes
do  fechamento da cápsula articular. Foram feitas dosagens de hemoglobina (mg/dL) e
hematócrito (%) no pré-operatório, após 24 e 48 horas da cirurgia. Foram aplicados o ques-
tionário Womac e a escala verbal da dor e medidas as amplitudes de movimento do joelho
até  o segundo mês pós-operatório. A análise estatística comparou os resultados a ﬁm de
comprovar haver diferenc¸a entre os grupos em cada um dos momentos da avaliac¸ão.
Resultados: Medidas do valor da hemoglobina (mg/dL) e hematócrito (%) feitas no pré-
operatório, após 24 e 48 horas da cirurgia, não mostraram diferenc¸as signiﬁcativas entre
os  grupos (p > 0,05). O questionário Womac e a amplitude de movimento medida no pré-
operatório e até os dois primeiros meses também não mostraram diferenc¸as estatísticas
entre os grupos (p > 0,05). A avaliac¸ão da dor por meio da escala verbal mostrou vantagem
no  grupo que usou o plasma rico em plaquetas após 24 e 48 horas, uma e três semanas e
dois meses de pós-operatório (p < 0,05).
Conclusões: Da maneira com que foi usado, o plasma rico em plaquetas não se mostrou
efetivo para reduzir sangramento ou melhorar a func¸ão do joelho após a artroplastia em
comparac¸ão  com os controles. Houve vantagem na escala verbal de dor pós-operatória.
©  2015 Sociedade Brasileira de Ortopedia e Traumatologia. Publicado por Elsevier
Editora Ltda. Todos os direitos reservados.
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dntroduction
otal knee arthroplasty is deemed to be successful when com-
lete tissue healing, pain control and good joint functioning
re achieved.1
Major postoperative bleeding frequently occurs.1,2 By min-
mizing the bleeding, the need for transfusion is avoided
nd formation of hematomas and seromas that might cause
ain, impairment of the range of motion, disorders of wound
ealing and prolonged hospital stays are prevented.2,3 Blood
ransfusion is subject to side effects, such as immunologi-
al reactions and infections.2,3 Infections may occur directly
hrough contamination4 or through greater susceptibility
nduced by means of immunomodulation.4 Use of autologous
lood has not been shown to be a better option than the
omologous blood that is routinely used.1,5,6 In an attempt
o reduce the bleeding, many  surgeons remove the tourniquet
rom the limb before closing the joint capsule and wound in
rder to achieve hemostasis. However, this not only increases
he duration of the operation but also does not present proven
fﬁcacy.1,7–9 Use of ﬁbrin glue, which is produced from human
lasma and, for this reason, is also subject to contamination
nd immunological reactions, has presented good results with
egard to controlling bleeding, through acting as a hemostatic
gent.10–13
10–12From the good initial results obtained with ﬁbrin glue,
ut bearing in mind the risks of cross-contamination and the
ifﬁculty in obtaining this agent,11 Whitman et al. (1997)14
escribed the use of concentrates of autologous platelets forimproving the healing. Antibacterial and antifungal effects
have also been observed recently.15
Since then, products containing growth factors derived
from platelets have been used under the name of platelet-
rich plasma (PRP), in a variety of situations within medicine
and dentistry.12 PRP is also known as platelet-enriched plasma
(PeRP), platelet-rich concentrate (PRC) or autologous platelet
gel.12 PRP has been produced by means of centrifugation of the
patient’s own blood, collected minutes before the surgery.2
The growth factors present in PRP are cytosines that come
from blood and are part of the natural healing process. This
process can be modiﬁed and accelerated according to the
concentration of these factors.15 These cytosines have an
important role in relation to cell proliferation, chemotaxis, cell
differentiation and angiogenesis.15
In 2000, during the congress of the American Academy of
Orthopedics, Mooar et al.16 demonstrated the use of autol-
ogous platelet gel during the postoperative period following
implantation of total knee prostheses, for the ﬁrst time, with
good results.
Starting in 2006, studies on the use of PRP subsequent to
total knee arthroplasty have been published, showing good
results.1–3,17 In these studies, use of PRP resulted in lower blood
loss, fewer blood transfusions, better healing, less postopera-
tive pain and infection and shorter hospital stay.1–3,17 Two
randomized prospective studies on this topic have been pub-
lished so far. One of them did not show any beneﬁt from PRP in
relation to the controls,18 while the other study showed some
beneﬁt from using PRP, but without any statistical difference
in the data relating to bleeding.17
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Table 1 – Model for the chart used to gather data on the parameters analyzed at the different assessment times, before
and after the operation.
Before 24 h after 48 h after 7 days after 21 days after 2 months after
Hb X X X
Ht X X X
ROM X X X X X X
Pain X X X X X X
WOMAC X X
Transfusion X X
Wound X X X X X
in, ve
d, ob
formed by the same surgeon, using the same instruments and
implanted material.Hb, hemoglobin; Ht, hematocrit; ROM, range of motion of the knee; Pa
Index19; Transfusion, evaluation of need for blood transfusion; Woun
The hypothesis of the present study was that use of PRP
would be effective for controlling pain and bleeding and would
improve the healing after total knee arthroplasty.
The aim of this study was to evaluate the efﬁcacy of PRP
with regard to healing, pain and hemostasis after total knee
arthroplasty.
Sample  and  methods
This was a blinded randomized clinical study. The project had
been approved by our institution’s research ethics committee.
Forty patients with an indication for total knee arthroplasty
who  were attended at our institution’s outpatient clinic were
selected.
The inclusion criteria were that the patient needed to have
received explanations about the study and to present three-
compartment osteoarthrosis of the knee. They could be of
either sex and needed to have an indication for total knee
prosthesis.
Patients presenting the following criteria were excluded: major
deformities that would lead to more  extensive bone cuts or
soft-tissue release; inﬂammatory diseases; or previous surgery
on the knee to be operated.
The patients were advised that, for inclusion in the study,
they needed to sign the free and informed consent statement
(Appendix 1).
Deﬁnition  of  the  groups
The experimental group (20 patients) underwent implanta-
tion of a total knee prosthesis and received an intra-articular
application of PRP.
The control group (20 patients) underwent implantation of
a total knee prosthesis without receiving any intra-articular
application of PRP.
The individuals were divided between the two groups ran-
domly by means of a draw. The patients were not informed
regarding the group to which they belonged and remained
totally unaware of this information until the end of the project.Data-gathering
Data-gathering (Table 1) before and after the operation com-
prised the following:rbal pain scale; WOMAC, Western Ontario and McMaster Universities
servation of any abnormalities of healing.
1. Serum hemoglobin (Hb) and hematocrit (Ht) tests per-
formed before the operation and 24 and 48 h after the
operation. The need for transfusion was evaluated.
2. Clinical examination of range of motion and pain. For
this, goniometry and a verbal pain scale (scores between
0 and 10, such that 0 was free from pain and 10 was
the worst pain) were used at the following times after
the operation: 24–48 h, seven days, 21 days and two
months. Any abnormalities of wound healing were also
noted.
3. To evaluate knee functioning before the operation and two
months after the operation, the WOMAC instrument was
used, in its version translated and validated for use in the
Portuguese language19 (Appendix 2).
The surgical technique was the one established in the
current literature, with medial patellar access and applica-
tion of PRP to the entire exposed portion of the joint, in the
cases selected for this (Figs. 1–6). All the procedures were per-Fig. 1 – Joint exposed after cementation.
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Fig. 2 – PRP immediately before application.
P
Fig. 4 – Application of PRP to the joint cavity.Fig. 3 – Application of PRP to the joint cavity.
ostoperative  protocol  used1. During the hospital stay, the following was used as an
analgesic: 1 g of dipyrone intravenously every six hours
and 100 mg  tramadol hydrochloride every eight hours;Fig. 5 – Closure of the joint capsule.
2. Patients with pain scored as more  than seven on the verbal
pain scale received 4 mg  of morphine intravenously every
four hours;
3. After discharge from hospital, the patients were pre-
scribed 1 g of dipyrone orally every six hours if pain
occurred, and 50 mg  of tramadol hydrochloride orally
every six hours if the pain continued even after taking
dipyrone;
4. All the patients received prophylaxis against deep vein
thrombosis comprising a dose of 40 mg  of enoxaparin
subcutaneously, 24–48 h after the surgery, and they were
prescribed 10 mg  of rivaroxaban daily, for a further 10 days
at home;
5. Antibiotic prophylaxis was administered, comprising 2 g
of cefazolin intravenously at the time when anesthesia
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Fig. 6 – Closure of the skin and subcutaneous tissue.
Fig. 7 – Plasma being removed.was induced, followed by 1 g of cefazolin every eight hours
for 48 h;
6. The dressing was changed at the hospital on the second
day after the operation, before discharge from the hos-
pital, in the outpatient clinic on the seventh day and at
home every day until the stitches were removed on the
21st day;
7. The patients used a walking frame for 21 days, with
full weight-bearing from the second postoperative day
onwards;
8. Physiotherapy was started while the patient was still in
hospital and was continued until the second postopera-
tive month after the operation;
9. Radiological examinations were performed on the knees
during the immediate postoperative period and in the out-
patient clinic of Santa Casa at the outpatient visit two
months after the operation;
10. The parameters evaluated at the return visits were as fol-
lows: pain and symptoms relating to the knee; range of
motion; satisfaction; and limb alignment and function-
ing (ability to walk, use of sticks, use of stairs and ramps,
sitting down  and standing up, etc.).
Preparation  of  the  PRP
The PRP was prepared by a professional with skills and training
for this process.
A sample of 20 mL  of blood was collected from each patient
in 5 mL  vacuum tubes containing 10% sodium citrate for anti-
coagulation. The tubes were centrifuged (Fanem®) at 1200 rpm
for 10 min, at room temperature in a centrifuge of radius
6.5 cm.  The result from this centrifugation enabled separation
of three components: red cells (bottom of the tube), white cells
(thin layer on top of the red cells) and plasma (top layer) (Fig. 7).The plasma was decanted into another sterile tube, of capacity
10 mL,  and was centrifuged again in the same machine at the
same speed, for ﬁve minutes. At the end of this centrifuga-
tion, the upper plasma layer that was obtained (accounting for
approximately 50%) was discarded because of the small quan-
tity of platelets. The lower portion, which was rich in platelets
and was named platelet-rich plasma, was placed in a sterile
Petri dish in the surgical ﬁeld. Following this, it was placed in a
syringe for the surgeon to apply. A proportion of the PRP from
every ﬁfth patient was separated out and subjected to analysis
on the number of platelets, in an automatic counter (ADVIA
120 Siemens®).
Statistical  analysis
For the variables Hb and Ht, the technique of analysis of
variance was used, in a model of repeated measurements in
independent groups, complemented by the Bonferroni multi-
ple comparisons test.20
In the evaluations on the range of motion, verbal pain scale
and functioning, the nonparametric model analysis of vari-
ance model of repeated measurements in independent groups
was used, complemented by the Dunn multiple comparisons
test.21
Results
The patients’ mean age was 67.7 years (range: 50–86). In
the PRP group, this mean was 66.4 years (range: 50–86) and
in the control group, 71.6 years (range: 55–81). The mean
duration of the operation was 91.4 min  (range: 70–105): 90.7
(80–105) in the PRP group and 91.5 (70–95) in the control
group. The distribution showed that there were 14 male
patients: six in the PRP group and eight in the control group
(Table 2).
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Table 2 – Mean and minimum and maximum values for
age, sex distribution and duration of surgery among the
patients.
PRP group Control group Total
Number of patients 20 20 40
Age (years) 66.4 (50–86) 71.6 (55–81) 67.7
Sex (M/F) 6/14 8/12 14/26
Duration of surgery
(min)
90.7  (80–105) 84.3 (70–95) 86.8 (70–105)
Transfusion 0 0 0
Table 3 – Platelet counts before the operation and in the
PRP preparation.
Platelet counts Serum
platelet assay
Platelet assay
on PRP
Patient 1 PRP group 316,000 950,000
Patient 6 PRP group 411,000 1,138,000
Patient 11 PRP group 223,000 777,000
p
q
s
c
f
between PRP preparations, blood samples were collected fromPatient 16 PRP group 416,000 1,088,000
In the platelet counts, it was found that in the cases of
oorest yield of platelets, the number was twice the initial
uantity present in the plasma of that patient. There were
ome patients for whom the platelet count after the second
entrifugation was four times as great (Table 3).
None of the patients in this study needed to have trans-
usions. The criterion for transfusion used here was a
Table 4 – Comparison between the PRP and control groups.
PRP 
Hemoglobin (mg/dL)
Before operation 11.610 (1.405) 
24 h after operation 10.285 (1.467) 
48 h after operation 9.605 (1.259) 
Hematocrit (%)
Before operation 35.030 (3.508) 
24 h after operation 30.930 (3.525) 
48 h after operation 29.225 (3.443) 
ROM (degrees)
Before operation 115 (45; 130) 
24 h after operation 55 (30; 85) 
48 h after operation 75 (60; 85) 
7 d after operation 82.5 (60; 100) 
21 d after operation 95 (60; 110) 
2 m after operation 97.5 (45; 120) 
Pain (scores from 0 to 10)
24 h after operation 6.0 (2.0; 8.0) 
48 h after operation 3.0 (0.0; 6.0) 
7 d after operation 2.0 (0.0; 3.0) 
21 d after operation 1.0 (0.0; 2.0) 
2 m after operation 0.0 (0.0; 2.0) 
WOMAC (between 0 and 96)
Before operation 45.5 (30.0; 54.0) 
2 m after operation 70.0 (59.0; 80.0) 
ROM, range of motion of the knee; Pain, verbal pain scale; WOMAC, Weste;5 0(2):186–194 191
hemoglobin concentration of less than 7 mg/dL in symp-
tomatic patients during the postoperative period. There were
three patients who presented dehiscence of the operative
wound and superﬁcial infection. These patients were treated
using dressings and oral antibiotics, and full healing was
achieved in these cases. Two of them were in the PRP group.
There were no cases of thromboembolism.
Table 4 shows that there were no statistically signiﬁcant
differences between the groups with regard to the pre and
postoperative values for the variables of hemoglobin, hema-
tocrit, range of motion or WOMAC questionnaire score.19 In
the pain assessment, there was a signiﬁcant advantage in the
group that used PRP.
Discussion
Variations in the ways of obtaining, preparing and apply-
ing PRP currently constitute a limitation on any comparison
between studies.22 A recent systematic review on PRP use in
chondral lesions consulted 254 citations and, after applying
rigorous exclusion criteria, selected 21 for study. Even so, 10%
of these did not report the method used for obtaining the
PRP and 28.6% did not report the platelet concentration of the
preparation.23
In another study that evaluates this common variationeach of the eight patients and these were subjected to three
different centrifugation methods. All of these methods con-
siderably increased the number of platelets in the concentrate,
Control p value
12.105 (1.611) >0.05
10.759 (1.686) >0.05
9.841 (1.454) >0.05
36.618 (4.803) >0.05
32.227 (5.199) >0.05
29.545 (4.381) >0.05
115 (55; 120) >0.05
55 (30; 85) >0.05
75 (55; 85) >0.05
82.5 (60; 100) >0.05
90 (45; 105) >0.05
95 (45; 120) >0.05
7.0 (4.0; 8.0) <0.05
4.0 (2.0; 6.0) <0.05
2.0 (1.0; 3.0) <0.05
2.0 (0.0; 3.0) <0.05
1.0 (0.0; 3.0) <0.05
46.0 (21.0; 60.0) >0.05
72.0 (0.0; 82.0) >0.05
rn Ontario and McMaster Universities Index.19
p . 2 0 
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but it was seen that there was variation in the growth fac-
tor concentrations between individuals and between different
samples from the same individual.24
The PRP preparation in this study followed techniques
that had previously been described.25,26 The platelet counting
proved that high concentrations were produced (between
two and four times the level in the plasma). In addition to
the platelet concentrations, the types of PRP can be differ-
entiated according to the concentration of leukocytes and
their form of activation.22 In the present study, the leuko-
cytes were separated from the PRP that was obtained, and we
chose endogenous platelet activation, i.e. done by means of
the collagen and other activation factors of the joint cavity
that was exposed.27 All the previous studies on applica-
tion of PRP in cases of knee arthroplasty presented (when
documented) platelet concentrations similar to those used
in the present study with leukocyte separation.1–3,17,18,28 In
these studies, the PRP was activated using calciﬁed throm-
bin, prior to application. Endogenous activation by means of
collagen shows a cytokine release pattern of longer dura-
tion, of a more  sustained nature than that of exogenous
activation27 and for this reason, it was done in the present
study. In the natural healing process, the collagen exposed
in the wounded tissue is frequently the initial activator and
generates platelet adhesion in a single layer over itself. Sub-
sequently, there is superposition of platelets by means of
the thrombin route. This manner, which is closer to the
natural method of delayed activation, is functionally use-
ful for ensuring that growth factor release does not occur
prematurely, i.e. before complete formation of a provisional
scaffold.27
In 2009, in the ﬁrst randomized controlled study on the use
of PRP in cases of knee arthroplasty that was published, no
beneﬁts were shown.18 The PRP used was activated before its
application in the form of a spray, and the bleeding was quan-
tiﬁed through the difference in hemoglobin values from before
the operation to 24 h after the operation. As reported earlier,
endogenous activation may have led to better results and,
as conﬁrmed in the present study, there was also a notable
decline in hemoglobin and hematocrit levels between 24 and
48 h after the operation.
In another randomized study in which PRP was used in
cases of total knee arthroplasty with the aim of reducing the
bleeding, its use did not make a signiﬁcant difference, even
though there was a positive difference in relation to the post-
operative bleeding.17 One of the possible reasons for this,
according to the authors of that study, was that their use of
drainage after the operation might have led to loss of PRP.17
For this reason, we  chose not to use drainage in the present
study. Nonetheless, we did not ﬁnd any statistically signiﬁ-
cant results in relation to bleeding. Another reason that was
pointed out as a possible cause of lack of statistical signiﬁ-
cance in the results from that study was the small number
of patients, which may have been the same limitation as in
the present study. This study also showed that the pain level
was lower in the group that used PRP in the postoperative
evaluation.17In our study, the analysis on pain, as shown by the ver-
bal pain scale, also showed that the group that used PRP
had an advantage. This advantage, which was not shown1 5;5 0(2):186–194
in the other variables analyzed, led to lower use of mor-
phine in this group during the hospital stay (only one patient
used it, versus three in the control group). Two months after
the operation, another analysis on pain using the verbal
scale still showed that the pain level in the PRP group was
better, although this was proven in the pain and function
questionnaire (WOMAC). It had already been documented in
a previous uncontrolled study that PRP had a positive effect
with regard to improvement of postoperative pain.3 PRP has
a proven anti-inﬂammatory effect and has been used with
this function in relation to other pathological conditions.29
This, therefore, may explain the results found in the present
study.
Despite the pain control proven in this and other stud-
ies, another recently published retrospective study on the use
of PRP in relation to knee prostheses, with more  than 200
patients and without the use of postoperative drains also did
not show any improvement in bleeding.28 In the present study,
the bleeding was measured through the decline in hemoglobin
levels, only 24 h after the operation.
In two patients in the PRP group and in only one in the con-
trol group, there was dehiscence of the suture and superﬁcial
infection. Thus, we did not ﬁnd any evidence in relation to
any antibacterial effect15 or any advantage in relation to heal-
ing of the operative wound. A previous study demonstrated
bacterial growth in PRP.30 Preparation of this, outside of the
laminar ﬂow hood, as done in the present study, may facilitate
contamination.
The limitations of the present study include the small num-
ber of patients, which may have interfered with the result from
the statistical analysis. Another factor relates to the study
design, which allowed the surgeon to be aware of the group
to which the patient belonged, at the time of performing the
operation. The lack of quantiﬁcation of the growth factors and
the number of residual leukocytes in the PRP samples is also
a factor that may have limited the discussion of the results
obtained.
Conclusion
In the manner in which PRP was used, it was not shown to
be effective for reducing the bleeding or improving the func-
tioning of the knee after arthroplasty, in comparison with the
controls. There was an advantage on the verbal scale for post-
operative pain.
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ppendix  1.  Free  and  informed  consent
tatement.
his study has the title “Platelet-rich plasma (PRP) applied
during total knee arthroplasty”.
Dr. João Paulo Fernandes Guerreiro, a doctor within the
clinical staff of Irmandade da Santa Casa de Londrina, will
conduct a clinical study within this institution that
involves total knee arthroplasty on 40 patients, using a
currently well-established surgical technique. In 20
patients, we  will apply platelet-rich plasma (PRP) before
closing the wound. PRP is a substance made from a sample
of the patient’s own blood, collected at the time of starting
the anesthesia.
The objective of the study is to analyze the beneﬁts that
PRP might bring toward controlling pain and bleeding and
improving healing.
PRP is a part of human blood that contains a large quantity
of platelets. Platelets are cells that participate in blood
coagulation when blood comes into contact with wounds.
The PRP used in this study will be removed from the same
patient during anesthesia.
Regarding the risks of the surgery, these include edema
(swelling), bleeding (with possible blood transfusion during
or after the operation) and/or hematoma; dehiscence of
the surgical wound (breakage of stitches or opening or the
surgical wound); postoperative pain; joint stiffness
(movement limitation); anesthetic accidents; complex
regional pain syndrome; venous thrombosis and its
consequences (formation of a coagulum that causes
obstruction of the veins); temporary or deﬁnitive functional
incapacity (in relation to activities of daily living, work
activities, sports or other activities); superﬁcial infection;
deep infection and its consequences (difﬁcult to treat and
eradicate, with the need for new hospitalizations and
surgical interventions for cleaning and removal of ﬁxation
materials, and probable sequelae such as functional
limitation or loss of the limb operated); neurovascular
injuries (injuries to nerves that may compromise the
sensitivity and movement  of a given region of the body
and/or limb; arterial lesions that may compromise the
blood irrigation of a given region and/or limb).
The mean time taken to perform the surgery is
100 minutes.
Evaluations will be made by means of physical
examinations during the hospital stay (generally for two
days after the surgery) and then at the following times
after the surgery: 7, 10 and 21 days; 2, 6 and 12 months;
and annually thereafter. Radiographs of the knee will be
performed 2, 6 and 12 months after the surgery and
annually thereafter, in the same way as is done routinely
among our patients.
During the postoperative period, it is common to have
some degree of pain, but this improves with the medication
that will be prescribed. There may be some swelling of the
knee, which can be treated with medication sand ice
compresses. Slight bleeding may also occur on the ﬁrst
days. Any other doubt should be clariﬁed with the doctor.;5 0(2):186–194 193
1.1. Therefore, we request your consent to include you in our
study and we assure you than conﬁdentiality will be maintained.
We will make use of your participation for the scientiﬁc
evaluation and possible publication of this study, within the
ethical principles that must guide research and our profession.
We  would also like to make it clear that your participation
will not imply any ﬁnancial remuneration. If your do not
wish to participate, you are free to opt out, both at the
outset or during the course of the work, without any
personal losses.
If you have any queries, you can contact the researcher
directly through this telephone number: (43) 3377 0900. In
an emergency, you can seek assistance at the orthopedic
emergency service of Santa Casa de Londrina, telephone:
(43) 3373 1671.
You may also contact the bioethics and research ethics
committee of Irmandade da Santa Casa de Londrina,
telephone: (43) 3373 1643.
We  thank you for your valuable contribution.
Researcher’s signature
I  declare that I have been informed about the study and I
agree to participate.
DATE:
Name
Signature
Appendix  2.  Western  Ontario  and  McMaster
Universities  Index  (WOMAC)
Category 1 – Severity of the pain (during the last month) in
relation to:
Walking: ( ) none ( ) mild ( ) moderate ( ) severe
Going up stairs: ( ) none ( ) mild ( ) moderate ( ) severe
Pain at night: ( ) none ( ) mild ( ) moderate ( ) severe
Pain when resting ( ) none ( ) mild ( ) moderate ( ) severe
When carrying weights: ( ) none ( ) mild ( ) moderate ( ) severe
Morning stiffness: ( ) none ( ) mild ( ) moderate ( ) severe
Protokinetic stiffness: ( ) none ( ) mild ( ) moderate ( ) severe
Category 2 – Level of difﬁculty in carrying out the following
functions:
Going down stairs: ( ) none ( ) mild ( ) moderate ( ) severe
Going up stairs: ( ) none ( ) mild ( ) moderate ( ) severe
Getting up from a chair: ( ) none ( ) mild ( ) moderate ( ) severe
Standing up: ( ) none ( ) mild ( ) moderate ( ) severe
Bending to the ground: ( ) none ( ) mild ( ) moderate ( ) severesevere
Getting into or out of a car: ( ) none ( ) mild ( ) moderate ( )
severe
p . 2 0 
r
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2194  r e v b r a s o r t o 
Shopping: ( ) none ( ) mild ( ) moderate ( ) severe
Putting socks on: ( ) none ( ) mild ( ) moderate ( ) severe
Getting out of bed: ( ) none ( ) mild ( ) moderate ( ) severe
Taking socks off: ( ) none ( ) mild ( ) moderate ( ) severe
Lying down  on a bed: ( ) none ( ) mild ( ) moderate ( ) severe
Getting into and out of a bath: ( ) none ( ) mild ( ) moderate ( )
severe
Sitting down: ( ) none ( ) mild ( ) moderate ( ) severe
Sitting down  on and getting up from the toilet:
( ) none ( ) mild ( ) moderate ( ) severe
Carrying out light domestic tasks:
( ) none ( ) mild ( ) moderate ( ) severe
Carrying out heavy domestic tasks:
( ) none ( ) mild ( ) moderate ( ) severe
Counting the points and calculating the score:
Response “none” – 4 points; “mild” – 3; “moderate” – 2; and
“severe” – 0.
Total number of points:
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